



3 Sector #5

Docket No.: 1195-003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT OPERATIONS

In re Application of)
Antonio Guarna et al.) Group Art Unit:
Serial No.: 09/593,173) Examiner:
Filed: June 12, 2000)

For: BENZO[C]QUINOLIZINE DERIVATIVES AND THEIR USE AS 5 ALPHA REDUCTASE INHIBITORS

New York, NY 10036
November 21, 2000

Assistant Commissioner for Patent
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

It is requested that the annexed Information Disclosure Statement be considered in connection with the above identified application.

J. Med. Chem. V.40, No.9 (1997) 1293-1313	Discloses treatments for prostate hyperplasia
J. Med. Chem. V.36, 4313-4315 (1993)	Discloses use of azasteroids for 5 alpha reductase inhibition
J. Med. Chem. V.37, 3871-3874 (1994)	Discloses use of azasteroids for 5 alpha reductase inhibition
J. Med. Chem. V.40, 1112-1129 (1997)	Discloses use of azasteroids for 5 alpha reductase inhibition
J. Med. Chem. V. 40 3466-3477 (1997)	Discloses use of azasteroids for 5 alpha reductase inhibition

It is requested that the cited references be considered in connection with the examination of the present application.

Respectfully submitted,

James V. Costigan
James V. Costigan
Reg. No. 25,669

MAILING ADDRESS:

HEDMAN, GIBSON & COSTIGAN, P.C.
1185 Avenue of the Americas
New York, NY 10036-2601
(212) 302-8989

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on 11/21/05.